The U.S. Food and Drug Administration (FDA) recently approved the use of Darzalex Faspro (daratumumab and hyaluronidase-fihj) ...
Multiple myeloma was once viewed as an incurable diagnosis, but Ameet Patel, MD, of Florida Cancer Specialists & Research ...
The management of treatment side effects can expand caregiver duties significantly, and can involve working more closely with ...
Experts discuss the importance of transitioning cancer care from academic centers to community practices, ensuring patient ...
Last week, the U.S. Food and Drug Administration (FDA) approved the use of Darzalex Faspro (daratumumab and ...
Recently, new immune-based treatments have shown impressive results when multiple myeloma returns, changing how doctors treat ...
Genetically modified immune cells can offer precious additional time to patients with advanced multiple myeloma. However, these therapies lose their impact as the molecules on cancer cells that immune ...
Even as Johnson & Johnson’s oncology superstar Darzalex Faspro racks up megablockbuster sales and reshapes the multiple ...
In an interview on the first-in-human phase 1 study of gintemetostat, Saad Z. Usmani, MD, PhD, detailed the initial safety ...
MedPage Today on MSN
Managing health-related quality of life in multiple myeloma
Palliative care that recognizes patient goals and values is essential, starting at diagnos ...
Darzalex Faspro, in combination with an anti-cancer triplet, is the first anti-CD38-based regimen for newly diagnosed patients with multiple myeloma, regardless of eligibility for stem cell ...
The International Myeloma Foundation (IMF) today welcomed Stephen L. Houff, MD, as the newest member of the IMF Board of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results